Monday, August 29, 2016

Big Pharma price-gouging with EpiPens

It's not related to diabetes, but if you pay attention to the headlines at all lately, you probably heard about the latest scandal in the pharmaceutical world: Mylan has raised the price of their EpiPens something like 450 percent, from $100 for a two-pack in 2007 to $600 now.  And they can't even claim they have to cover the cost of inventing the drug, since they actually only bought the rights to the patent from another company.

So what have they been spending their money on?  Their CEO's salary, apparently, which has also jumped since then, from $2 million to $19 million.